Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.
Fill Out Your Profile to share more about you. Learn more...

New BCO Content on Recently Approved Immunotherapy Jemperli


Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available.

Jemperli also is approved to treat dMMR advanced-stage endometrial cancer that has grown after treatment with platinum chemotherapy.

Learn more about:

Read more.